We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.
- Authors
Ji Hyung Hong; Sung-Eun Lee; Soo Young Choi; Soo-Hyun Kim; Eun-Jung Jang; Ju-Hee Bang; Jin Eok Park; Hye-Rim Jeon; Yun Jeong Oh; Jeong-Eun Yi; Hae Ok Jung; Ho Joong Youn; Dong-Wook Kim
- Abstract
We describe two cases of pulmonary arterial hypertension (PAH) that occurred under dasatinib treatment and were resolved after dasatinib discontinuation. Two patients with chronic phase chronic myeloid leukemia (CML) were switched to dasatinib therapy because of hematological progress while receiving imatinib. These patients had New York Heart Association (NYHA) functional class II dyspnea with elevated right ventricular systolic pressure (RVSP), which progressed under dasatinib treatment. After dasatinib treatment was discontinued, subjective symptoms were improved to NYHA functional class I and the follow-up transthoracic Doppler echocardiography showed improved RVSP. Treatment with an alternate tyrosine kinase inhibitor was initiated and had been continued without development of dyspnea or elevation of RVSP. This report suggests that dasatinib can cause the reversible PAH, therefore, routine cardiopulmonary evaluation before and during treatment with dasatinib may be needed in CML patients with clinical manifestations.
- Subjects
DASATINIB; CHRONIC myeloid leukemia; IMATINIB; DYSPNEA; DOPPLER echocardiography; PATIENTS
- Publication
Cancer Research & Treatment, 2015, Vol 47, Issue 4, p937
- ISSN
1598-2998
- Publication type
Case Study
- DOI
10.4143/crt.2013.155